search
Back to results

Glucomannan for Childhood Functional Constipation.

Primary Purpose

Functional Constipation

Status
Completed
Phase
Phase 3
Locations
Poland
Study Type
Interventional
Intervention
Glucomannan
maltodextrin
Sponsored by
Medical University of Warsaw
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Functional Constipation focused on measuring constipation, children

Eligibility Criteria

3 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • functional constipation diagnosed according to Rome Criteria III (duration of symptoms for at least 2 months prior to study inclusion)
  • age 3 to 16 years
  • informed consent from parents and/or child

Exclusion Criteria:

  • organic cause of defecation disorders (Hirschsprung's disease, spinal anomalies or anorectal pathology; history of gastro-intestinal surgery)
  • mental retardation
  • metabolic disease (e.g. hypothyroidism)
  • irritable bowel syndrome
  • intake of medications influencing gastrointestinal motility

Sites / Locations

  • Department of Paediatrics, The Medical University of Warsaw, Poland

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Glucomannan

Placebo

Arm Description

glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks

maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks

Outcomes

Primary Outcome Measures

treatment success
paasing at least 3 stools per week with no episodes of soiling

Secondary Outcome Measures

stool frequency
number of stools passes per week
soiling
number of episodes of soiling per week
hard stools or painful defecations
number of hard stools passed or painful defecations per week
abdominal pain
number of episodes of abdominal pain per week
need for interventional laxative
need for rescue treatment (osmotic laxative: lactulose 1 ml of syrup per 1 kg of body weight) when no stool passed for 3 consecutive days)
flatulence
number of episodes of flatulence per 1 week
adverse events
any adverse events (mild or seriuos) reported by parents during the study period(pain, infections, hospitalizations, accidents or any other event related or not related to study intervention)

Full Information

First Posted
May 7, 2010
Last Updated
February 22, 2017
Sponsor
Medical University of Warsaw
search

1. Study Identification

Unique Protocol Identification Number
NCT01151878
Brief Title
Glucomannan for Childhood Functional Constipation.
Official Title
Glucomannan in Treating Childhood Functional Constipation: a Randomized, Double-blind, Placebo-controlled Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
June 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of Warsaw

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether administration of glucomannan (dietary fiber) is effective in treating functional constipation in children.
Detailed Description
Constipation is a common condition in children. In many patients symptoms persist to adulthood and decrease quality of life. The standard treatment, mostly osmotic laxatives such as lactulose or polyethyleneglycols, are often ineffective and may cause adverse events. Therefore, alternative treatment measures are being searched for. Glucomannan, a water-soluble fiber polysaccharide from the tubers of the Japanese Konjac plant, has been reported to be effective in constipated children. To date, 2 randomized trials were performed.1,2 One evaluated the effect as glucomannan as an adjunct to standard treatment.1 Another was conducted in neurologically impaired children, who constitute a specific population that cannot be compared to patients with functional constipation.2 In both trials, the number of patients was relatively small. Well-powered, randomized controlled study is required to evaluate clinical effectiveness of glucomannan as a sole treatment in childhood functional constipation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Constipation
Keywords
constipation, children

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The participants and researchers conducting the study were blinded. Intervention products were prepared in sachets centrally by the hospital pharmacy by a person not involved in the conduct of the trial. The active product and placebo were packaged in identical sachets and labeled with one of two codes, each allocated to the experimental product or placebo. This procedure was performed by an independent pharmacist, who was the only person aware of the codes' meaning. The appearance and texture of the dry products were identical.
Allocation
Randomized
Enrollment
92 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Glucomannan
Arm Type
Experimental
Arm Description
glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Glucomannan
Other Intervention Name(s)
Dicoman Junior, Vitis Pharma
Intervention Description
1.26 g per sachet; 2 sachets per day for 4 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
maltodextrin
Intervention Description
prepared in sachets (1.3g); 2 sachets per day for 4 weeks
Primary Outcome Measure Information:
Title
treatment success
Description
paasing at least 3 stools per week with no episodes of soiling
Time Frame
1 week
Secondary Outcome Measure Information:
Title
stool frequency
Description
number of stools passes per week
Time Frame
1 week
Title
soiling
Description
number of episodes of soiling per week
Time Frame
1 weeks
Title
hard stools or painful defecations
Description
number of hard stools passed or painful defecations per week
Time Frame
1 week
Title
abdominal pain
Description
number of episodes of abdominal pain per week
Time Frame
1 week
Title
need for interventional laxative
Description
need for rescue treatment (osmotic laxative: lactulose 1 ml of syrup per 1 kg of body weight) when no stool passed for 3 consecutive days)
Time Frame
1 week
Title
flatulence
Description
number of episodes of flatulence per 1 week
Time Frame
1 week
Title
adverse events
Description
any adverse events (mild or seriuos) reported by parents during the study period(pain, infections, hospitalizations, accidents or any other event related or not related to study intervention)
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: functional constipation diagnosed according to Rome Criteria III (duration of symptoms for at least 2 months prior to study inclusion) age 3 to 16 years informed consent from parents and/or child Exclusion Criteria: organic cause of defecation disorders (Hirschsprung's disease, spinal anomalies or anorectal pathology; history of gastro-intestinal surgery) mental retardation metabolic disease (e.g. hypothyroidism) irritable bowel syndrome intake of medications influencing gastrointestinal motility
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hania Szajewska, Professor
Organizational Affiliation
The Medical University of Warsaw
Official's Role
Study Director
Facility Information:
Facility Name
Department of Paediatrics, The Medical University of Warsaw, Poland
City
Warsaw
ZIP/Postal Code
01-183
Country
Poland

12. IPD Sharing Statement

Citations:
PubMed Identifier
16678565
Citation
Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006 Apr;130(5):1519-26. doi: 10.1053/j.gastro.2005.11.065.
Results Reference
background
PubMed Identifier
20180788
Citation
Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010 May;31(9):938-49. doi: 10.1111/j.1365-2036.2010.04273.x. Epub 2010 Feb 20.
Results Reference
result
PubMed Identifier
18713795
Citation
Pijpers MA, Tabbers MM, Benninga MA, Berger MY. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures. Arch Dis Child. 2009 Feb;94(2):117-31. doi: 10.1136/adc.2007.127233. Epub 2008 Aug 19. Erratum In: Arch Dis Child. 2009 Aug;94(8):649.
Results Reference
result
PubMed Identifier
14993586
Citation
Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation. Pediatrics. 2004 Mar;113(3 Pt 1):e259-64. doi: 10.1542/peds.113.3.e259.
Results Reference
result
PubMed Identifier
10636972
Citation
Staiano A, Simeone D, Del Giudice E, Miele E, Tozzi A, Toraldo C. Effect of the dietary fiber glucomannan on chronic constipation in neurologically impaired children. J Pediatr. 2000 Jan;136(1):41-5. doi: 10.1016/s0022-3476(00)90047-7.
Results Reference
result
PubMed Identifier
21320737
Citation
Chmielewska A, Horvath A, Dziechciarz P, Szajewska H. Glucomannan is not effective for the treatment of functional constipation in children: a double-blind, placebo-controlled, randomized trial. Clin Nutr. 2011 Aug;30(4):462-8. doi: 10.1016/j.clnu.2011.01.012. Epub 2011 Feb 12.
Results Reference
derived
Links:
URL
http://www.romecriteria.org/pdfs/adultFunctGIQ.pdf
Description
Rome Criteria III

Learn more about this trial

Glucomannan for Childhood Functional Constipation.

We'll reach out to this number within 24 hrs